WO2008127607A2 - Cardiac repair, resizing and reshaping using the venous system of the heart - Google Patents

Cardiac repair, resizing and reshaping using the venous system of the heart Download PDF

Info

Publication number
WO2008127607A2
WO2008127607A2 PCT/US2008/004613 US2008004613W WO2008127607A2 WO 2008127607 A2 WO2008127607 A2 WO 2008127607A2 US 2008004613 W US2008004613 W US 2008004613W WO 2008127607 A2 WO2008127607 A2 WO 2008127607A2
Authority
WO
WIPO (PCT)
Prior art keywords
heart
occluding agent
pattern
cardiac
venous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/004613
Other languages
English (en)
French (fr)
Other versions
WO2008127607A3 (en
Inventor
Hani N. Sabbah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Priority to EP08742708A priority Critical patent/EP2146667A2/en
Priority to AU2008239681A priority patent/AU2008239681B2/en
Priority to CA2682160A priority patent/CA2682160C/en
Priority to JP2010503052A priority patent/JP2010523264A/ja
Publication of WO2008127607A2 publication Critical patent/WO2008127607A2/en
Anticipated expiration legal-status Critical
Publication of WO2008127607A3 publication Critical patent/WO2008127607A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478—Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A61B17/12045—Type of occlusion temporary occlusion double occlusion, e.g. during anastomosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12195—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices comprising a curable material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00491—Surgical glue applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A61B2017/048—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery for reducing heart wall tension, e.g. sutures with a pad on each extremity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/12127—Double occlusion, e.g. for creating blood-free anastomosis site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2451—Inserts in the coronary sinus for correcting the valve shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30581—Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid
    • A61F2002/30583—Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid filled with hardenable fluid, e.g. curable in-situ
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0085—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof hardenable in situ, e.g. epoxy resins

Definitions

  • FIG. 4 is a sectional view of a retrograde injection through a vein wall into a venous system segment having a downstream occluder in place.
  • FIG. 14B is a posterior plan view of the heart of FIG. 14A.
  • FIG. 15B is a posterior plan view of the heart of FIG. 15A.
  • FIG. 24 is a 4x enlarged view of a first part of the heart section of
  • FIG. 23 is a 4x enlarged view of a second part of the heart section of FIG. 23.
  • FIG. 31 is a ventriculograph of a postreatment heart in end- systole.
  • veins are highly distensible and have little elastic recoil, so that unblocked veins in proximity to blocked veins can easily distend to accommodate additional volumes of blood from the occluded vein with only a small increase in venous pressure.
  • Identifying the sections of the cardiac venous system into which a suitable occlusion agent may be placed may be done empirically. Alternatively, computer-aided selection may be practiced if desired.
  • finite element model simulation is used to model a region of the heart such as the left ventricle.
  • parameters of the patient's left ventricle, including the location, extent and thickness of damaged wall areas are measured and added to the model.
  • Injection of material into selected segments of the venous system may be simulated by changing the transmural coordinates of epicardial and endocardial mesh nodes in border zone elements corresponding to the selected segments, along with changing the contractility of the elements.
  • FIG. 11A is an anterior plan view and FIG. 11B is a posterior view of a heart in which the distribution of the occluding agent sites 111-119 is slightly different than the distribution of the occluding agent sites 101-109 (FIGS. 10A and 10B).
  • the pattern may be envisioned as a line 110 which circumferentially spans across most of the left ventricle free wall at the near widest part of the ventricle, but at a slightly different location than the line 100 (FIGS. 10A and 10B).
  • the different locations of the lines 100 and 110 in FIGS. 10 and 11 may differently impact the reshaping achieved by the respective patterns.
  • the line 110 is shown as being slightly spaced away from the occluding agent sites so that the sites 111- 119 can be better identified on the heart.
  • the occluding agent sites 182 and 184 are also identified by the reference numerals 192 and 194 respectively to indicate that they may be envisioned as generally conforming to both the lines 180 and 190.
  • the free wall runs from anterior and anterior lateral and around the back of this view to the posterior lateral surface of the heart.
  • the lines 170, 180, 190 and 200 are shown as being slightly spaced away from the occluding agent sites 171-173, 181-186, 191-195 and 200-201 so that these sites can be better identified on the heart.
  • This channel may be used to provide access for implanting a mechanical strut of the type discussed above.
  • a suitable instrument is disclosed in U.S. Patent 6,132,451 issued October 17, 2000 to Payne et al., which hereby are incorporated herein in their entirety by reference thereto.
  • Implantable mechanical devices may also be drug-eluting to administer further treatment.
  • Rapidly growing cells and rapid growth-promoting biologies may also be used as occluding agent, whether natural or genetically manipulated.
  • the posterior wall thickness increased 7.0% while the thicknesses of the septal wall and the anterior wall were essentially unchanged at 0.0% and -0.9% respectively.
  • the cardiac wall receiving treatment thickened while the other cardiac walls did not.
  • the wall thickening did not affect the performance of the.healthy heart, in which end diastolic volume, end systolic volume, and ejection fraction were essentially unchanged.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Surgical Instruments (AREA)
PCT/US2008/004613 2007-04-11 2008-04-10 Cardiac repair, resizing and reshaping using the venous system of the heart Ceased WO2008127607A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08742708A EP2146667A2 (en) 2007-04-11 2008-04-10 Cardiac repair, resizing and reshaping using the venous system of the heart
AU2008239681A AU2008239681B2 (en) 2007-04-11 2008-04-10 Cardiac repair, resizing and reshaping using the venous system of the heart
CA2682160A CA2682160C (en) 2007-04-11 2008-04-10 Cardiac repair, resizing and reshaping using the venous system of the heart
JP2010503052A JP2010523264A (ja) 2007-04-11 2008-04-10 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US92293007P 2007-04-11 2007-04-11
US60/922,930 2007-04-11
US93410907P 2007-06-11 2007-06-11
US93411107P 2007-06-11 2007-06-11
US93404207P 2007-06-11 2007-06-11
US60/934,109 2007-06-11
US60/934,042 2007-06-11
US60/934,111 2007-06-11

Publications (2)

Publication Number Publication Date
WO2008127607A2 true WO2008127607A2 (en) 2008-10-23
WO2008127607A3 WO2008127607A3 (en) 2009-10-22

Family

ID=39864585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004613 Ceased WO2008127607A2 (en) 2007-04-11 2008-04-10 Cardiac repair, resizing and reshaping using the venous system of the heart

Country Status (6)

Country Link
US (2) US7875017B2 (https=)
EP (1) EP2146667A2 (https=)
JP (1) JP2010523264A (https=)
AU (1) AU2008239681B2 (https=)
CA (1) CA2682160C (https=)
WO (1) WO2008127607A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875017B2 (en) 2007-04-11 2011-01-25 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
US9375313B2 (en) 2006-09-08 2016-06-28 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
US10576123B2 (en) 2008-10-06 2020-03-03 3-D Matrix, Ltd. Tissue occluding agent comprising an IEIKIEIKIEIKI peptide
US10654893B2 (en) 2014-03-10 2020-05-19 3-D Matrix, Ltd. Self-assembling peptide compositions
US10793307B2 (en) 2012-07-06 2020-10-06 3-D Matrix, Ltd. Fill-finish process for peptide solutions
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
US11090398B2 (en) 2014-03-10 2021-08-17 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
WO2025250182A1 (en) * 2024-05-29 2025-12-04 Lifebridge Technologies Llc Heart pump that structures end-diastolic ventricular geometry for optimal filling and ventricular pump function

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US9238046B2 (en) 2007-09-21 2016-01-19 The Trustees Of The University Of Pennsylvania Prevention of infarct expansion
US20090259210A1 (en) * 2008-04-10 2009-10-15 Sabbah Hani N Method, apparatus and kits for forming structural members within the cardiac venous system
US20120041393A1 (en) * 2008-09-05 2012-02-16 Henry Ford Health System Apparatus and Method for Capsule Formation in Tissue
EP3246038B1 (en) 2008-09-30 2021-04-07 The Regents of the University of California Compositions comprising decellularized extracellular matrix obtained from cardiac tissue
US10143455B2 (en) 2011-07-20 2018-12-04 Covidien LLP Enhanced ultrasound visualization of intravascular devices
EP2398402B1 (en) 2009-02-20 2016-04-20 Covidien LP Devices for venous occlusion for the treatment of venous insufficiency
CA2808225C (en) 2010-08-24 2019-02-12 The Regents Of The University Of California Compositions and methods for cardiac therapy
WO2013036708A2 (en) 2011-09-07 2013-03-14 The Regents Of The University Of California Compositions and methods for tissue repair with extracellular matrices
US9168352B2 (en) 2011-12-19 2015-10-27 Cardiacassist, Inc. Dual lumen cannula
US8808620B1 (en) 2012-02-22 2014-08-19 Sapheon, Inc. Sterilization process design for a medical adhesive
EP3698815B1 (en) 2014-03-21 2024-02-21 University of Pittsburgh- Of the Commonwealth System of Higher Education Terminally sterilized hydrogel derived from extracellular matrix
US11406736B2 (en) 2016-01-13 2022-08-09 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Vascular extracellular matrix hydrogel
WO2019099863A1 (en) * 2017-11-17 2019-05-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Scaffolds having material properties optimized for cardiac applications and uses thereof
AU2018448387A1 (en) * 2018-11-07 2021-04-29 Baxter Healthcare Sa Dual check valve one handed applicator
US20240299018A1 (en) * 2023-03-07 2024-09-12 Medtronic, Inc. Occlusion device

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US6132451A (en) 1995-06-07 2000-10-17 Eclipse Surgical Technologies, Inc. Optical fiber for myocardial channel formation
US6283951B1 (en) 1996-10-11 2001-09-04 Transvascular, Inc. Systems and methods for delivering drugs to selected locations within the body
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP1707233A3 (en) 1996-02-02 2006-12-20 Medtronic Vascular, Inc. Apparatus for blocking flow through blood vessels
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
AU4648697A (en) 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US6183411B1 (en) 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
US6077214A (en) 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6406420B1 (en) 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US6045565A (en) 1997-11-04 2000-04-04 Scimed Life Systems, Inc. Percutaneous myocardial revascularization growth factor mediums and method
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
KR20010012313A (ko) 1997-05-06 2001-02-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
US7031775B2 (en) 1997-11-07 2006-04-18 Medtronic, Inc. Method and system for myocardial infarction repair
US6096021A (en) 1998-03-30 2000-08-01 The University Of Virginia Patent Foundation Flow arrest, double balloon technique for occluding aneurysms or blood vessels
US6085754A (en) 1998-07-13 2000-07-11 Acorn Cardiovascular, Inc. Cardiac disease treatment method
US6547821B1 (en) 1998-07-16 2003-04-15 Cardiothoracic Systems, Inc. Surgical procedures and devices for increasing cardiac output of the heart
US6360749B1 (en) 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US6685627B2 (en) * 1998-10-09 2004-02-03 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
JP2002531217A (ja) 1998-12-04 2002-09-24 チャンドラシェカー ピー． パサック， 生体適合性架橋ポリマー
US6689103B1 (en) 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
CA2378643A1 (en) 1999-07-23 2001-02-01 Diacrin, Inc. Muscle cells and their use in cardiac repair
US20030113301A1 (en) 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
US6709427B1 (en) 1999-08-05 2004-03-23 Kensey Nash Corporation Systems and methods for delivering agents into targeted tissue of a living being
US6926689B2 (en) 2002-03-13 2005-08-09 Albertus Scheule Aortic balloon occlusion cannula
US6575932B1 (en) 1999-12-02 2003-06-10 Ottawa Heart Institute Adjustable multi-balloon local delivery device
US6508824B1 (en) 2000-02-18 2003-01-21 Transvascular, Inc. Catheter-based methods for enlarging blood vessels to facilitate the formation of penetration tracts, fistulas and/or blood flow channels
JP2004505886A (ja) 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
US6537198B1 (en) 2000-03-21 2003-03-25 Myocor, Inc. Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly
US6585716B2 (en) 2000-04-05 2003-07-01 Biocardia, Inc. Method of treating the heart
US6730016B1 (en) 2000-06-12 2004-05-04 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
EP1311657A2 (en) 2000-08-21 2003-05-21 Rice University Tissue engineering scaffolds promoting matrix protein production
US7491385B2 (en) 2001-09-05 2009-02-17 Genegrafts Ltd. Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
US20020077687A1 (en) 2000-12-14 2002-06-20 Ahn Samuel S. Catheter assembly for treating ischemic tissue
US6620095B2 (en) 2000-12-22 2003-09-16 Syde A. Taheri Cradle-assisted myocardial repair and treatment
US7740623B2 (en) 2001-01-13 2010-06-22 Medtronic, Inc. Devices and methods for interstitial injection of biologic agents into tissue
US20040214760A1 (en) 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
US20030211793A1 (en) 2001-03-05 2003-11-13 Eugene Bell Injectable bio-compatible material and methods of use
WO2002087481A1 (en) * 2001-04-27 2002-11-07 Myomend, Inc. Prevention of myocardial infarction induced ventricular expansion and remodeling
US7311731B2 (en) 2001-04-27 2007-12-25 Richard C. Satterfield Prevention of myocardial infarction induced ventricular expansion and remodeling
US20020188170A1 (en) 2001-04-27 2002-12-12 Santamore William P. Prevention of myocardial infarction induced ventricular expansion and remodeling
CA2453658C (en) 2001-07-16 2013-04-16 Relaxis Ltd. In-vivo method and device for improving diastolic function of the left ventricle
EP1420702B1 (en) 2001-08-31 2005-04-20 Boston Scientific Limited Percutaneous pringle occlusion device
CA2465672A1 (en) 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
IL161862A0 (en) 2001-11-08 2005-11-20 Univ California Methods and compositions for correction of cardiac conduction disturbances
CN1649641A (zh) 2002-05-08 2005-08-03 加利福尼亚大学董事会 形成非切除性心脏传导阻滞的系统和方法
AU2003237824B9 (en) 2002-05-08 2008-06-19 The Regents Of The University Of California System and method for treating cardiac arrhythmias with fibroblast cells
US20040106896A1 (en) 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
AU2003234520A1 (en) 2002-05-08 2003-11-11 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
JP4224608B2 (ja) * 2002-11-19 2009-02-18 学校法人日本大学 注入療法用装置
CA2513726C (en) 2003-01-27 2014-08-12 Corassist Cardiovascular Ltd. In vivo device for improving diastolic ventricular function
US7840262B2 (en) 2003-03-10 2010-11-23 Impulse Dynamics Nv Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
CN100393367C (zh) 2003-05-05 2008-06-11 宾-古里安尼格夫大学研究及发展部 可注射的交联聚合制剂及其应用
EP1786502A2 (en) 2004-07-15 2007-05-23 Incumed Device and method for treating a blood vessel
SG156681A1 (en) 2004-11-09 2009-11-26 Cv Therapeutics Inc Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
US7226440B2 (en) 2005-01-31 2007-06-05 G & L Consulting, Llc Method and device for accessing a pericardial space
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20060253068A1 (en) 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
WO2007002554A2 (en) 2005-06-23 2007-01-04 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20070093748A1 (en) 2005-06-23 2007-04-26 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20070172472A1 (en) 2005-06-23 2007-07-26 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
US20070100199A1 (en) * 2005-11-03 2007-05-03 Lilip Lau Apparatus and method of delivering biomaterial to the heart
US20080138416A1 (en) 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
JP2010502372A (ja) 2006-09-08 2010-01-28 シンフォニー メディカル， インコーポレイテッド 心臓の局所的な異常の治療のための心筋内パターン形成
WO2008127607A2 (en) 2007-04-11 2008-10-23 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
US20090259210A1 (en) 2008-04-10 2009-10-15 Sabbah Hani N Method, apparatus and kits for forming structural members within the cardiac venous system

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375313B2 (en) 2006-09-08 2016-06-28 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
US7875017B2 (en) 2007-04-11 2011-01-25 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
US8419711B2 (en) 2007-04-11 2013-04-16 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
US11801281B2 (en) 2008-10-06 2023-10-31 3-D Matrix, Ltd. Tissue occluding agent comprising an ieikieikieiki peptide
US10596225B2 (en) 2008-10-06 2020-03-24 3-D Matrix, Ltd. Tissue occluding agent comprising an IEIKIEIKIEIKI peptide
US10576123B2 (en) 2008-10-06 2020-03-03 3-D Matrix, Ltd. Tissue occluding agent comprising an IEIKIEIKIEIKI peptide
US10793307B2 (en) 2012-07-06 2020-10-06 3-D Matrix, Ltd. Fill-finish process for peptide solutions
US12006085B2 (en) 2012-07-06 2024-06-11 3-D Matrix, Ltd. Fill-finish process for peptide solutions
US10654893B2 (en) 2014-03-10 2020-05-19 3-D Matrix, Ltd. Self-assembling peptide compositions
US11090398B2 (en) 2014-03-10 2021-08-17 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
US12115264B2 (en) 2014-03-10 2024-10-15 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
WO2025250182A1 (en) * 2024-05-29 2025-12-04 Lifebridge Technologies Llc Heart pump that structures end-diastolic ventricular geometry for optimal filling and ventricular pump function

Also Published As

Publication number Publication date
US20110087190A1 (en) 2011-04-14
US20080269720A1 (en) 2008-10-30
AU2008239681B2 (en) 2013-10-03
JP2010523264A (ja) 2010-07-15
EP2146667A2 (en) 2010-01-27
US7875017B2 (en) 2011-01-25
CA2682160C (en) 2017-04-04
WO2008127607A3 (en) 2009-10-22
CA2682160A1 (en) 2008-10-23
US8419711B2 (en) 2013-04-16
AU2008239681A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
US7875017B2 (en) Cardiac repair, resizing and reshaping using the venous system of the heart
AU2007292923B2 (en) Intramyocardial patterning for global cardiac resizing and reshaping
US20090012413A1 (en) Cardiac patterning for improving diastolic function
CA2619279A1 (en) Apparatus and method of delivering biomaterial to the heart
JP5667560B2 (ja) 心臓静脈系内に構造部材を形成するための方法、装置およびキット
AU2013204863A1 (en) lntramyocardial patterning for global cardiac resizing and reshaping
CN110876654A (zh) 一种用于血管病变的治疗系统及其应用

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2682160

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008742708

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010503052

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008239681

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008239681

Country of ref document: AU

Date of ref document: 20080410

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE